2 g (n = 47) | 4 g (n = 39) | OR | OR 95% CI | p value | |
---|---|---|---|---|---|
Analysis of neutrophil count | |||||
Neutropenic | 8 (17%) | 6 (15.4%) | 0.89 | 0.26–2.63 | > 0.999 |
Analysis of platelet count | |||||
Thrombocytopenia | 0 (0%) | 3 (7.7%) | N/A | N/A | 0.089 |
Analysis of ALT level | |||||
ALT > 3 × upper limit | 5 (10.6%) | 2 (5.1%) | 0.45 | 0.87–2.36 | 0.448 |
Analysis of ALP level | |||||
ALP > 3 × upper limit | 1 (2.1%) | 0 | N/A | N/A | > 0.999 |
Treatment cessation due to adverse effects | |||||
Treatment cessation due to adverse effects | 2 (4.3%) | 3 (7.7%) | 1.86 | 0.36–10.92 | 0.655 |